-
Apr 6, 2024 | 
nature.com | Jamie Felton |S. Alice Long |Suna Onengut-Gumuscu |Stephen S. Rich |dianna perez |Linda A. DiMeglio | +2 more
AbstractIslet autoantibodies form the foundation for type 1 diabetes (T1D) diagnosis and staging, but heterogeneity exists in T1D development and presentation. We hypothesized that autoantibodies can identify heterogeneity before, at, and after T1D diagnosis, and in response to disease-modifying therapies.
-
Apr 4, 2024 | 
jamanetwork.com | Michael Fang |Dan Wang |Elizabeth Selvin |Linda A. DiMeglio
Prevalence of Type 1 Diabetes Among US Children and Adults by Age, Sex, Race, and Ethnicity
Infections in Early Life and Development of Type 1 Diabetes
Andreas Beyerlein, PhD; Ewan Donnachie, MSc; Sibille Jergens, MSc; Anette-Gabriele Ziegler, MD
Maternal Type 1 Diabetes and Risk of Autism in Offspring
Anny H. Xiang, PhD; Xinhui Wang, PhD; Mayra P. Martinez, MPH; Kathleen Page, MD; Thomas A. Buchanan, MD; R.
-
Oct 4, 2023 | 
nature.com | S. Alice Long |Suna Onengut-Gumuscu |Stephen S. Rich |Linda A. DiMeglio |Emily Sims
AbstractType 1 diabetes (T1D) results from immune-mediated destruction of insulin-producing beta cells. Prevention efforts have focused on immune modulation and supporting beta cell health before or around diagnosis; however, heterogeneity in disease progression and therapy response has limited translation to clinical practice, highlighting the need for precision medicine approaches to T1D disease modification.
-
Aug 30, 2023 | 
hcplive.com | Steve Edelman |Linda A. DiMeglio |Egils K. Bogdanovics |Justin Gregory |Schafer Boeder
Steve Edelman, MD: What can we do with our patients to bridge the gap until we have a more solid cure? I think I can start off, and then Linda can jump in, or anybody. Are these hybrid closed-loop systems? We have 4 different ones on the market. I think you all would agree with automatic insulin delivery, modulating basal rate, alerts, and alarms that you could set individually that, for adults with type 1, my clinic has gotten so boring.
-
Aug 30, 2023 | 
hcplive.com | Steve Edelman |Linda A. DiMeglio |Egils K. Bogdanovics |Justin Gregory |Schafer Boeder
Steve Edelman, MD: Schafer, take us beyond stage 2. We got prevention, preservation once you already have T1D [type 1 diabetes], and replacement. I know Schafer was involved in islet cell encapsulated therapies, so talk a little bit about that. It’s the future, nothing approved at the current time, but I think it’s important to mention it. Schafer Boeder, MD: It’s interesting.
-
Aug 23, 2023 | 
hcplive.com | Steve Edelman |Linda A. DiMeglio |Egils K. Bogdanovics |Justin Gregory |Schafer Boeder
Steve Edelman, MD: As endocrinologists, what’s our role in pediatric or adult diabetes in making and getting teplizumab accessible for families? It’s like anything that you don’t have insurance for: it’s quite expensive. Do you have any ideas along those lines? We don’t work for the company, but there are programs. The company that owns teplizumab hired a third party to help with reimbursement, and there are financial assistance programs. Does anybody have anything to add to that? Justin M.
-
Aug 23, 2023 | 
hcplive.com | Steve Edelman |Linda A. DiMeglio |Egils K. Bogdanovics |Justin Gregory |Schafer Boeder
Steve Edelman, MD: Teplizumab has been around since 2002. It’s been owned by a couple of different companies. TrialNet owned it for a while, and then it was purchased by a different company. They finished the clinical trials. Are there any long-term things to follow up on your patients? They made it past the infusion, and most patients do extremely well. How are you following them over the long term? Justin M. Gregory, MD, MSCI: That’s an open question.
-
Aug 16, 2023 | 
hcplive.com | Steve Edelman |Linda A. DiMeglio |Egils K. Bogdanovics |Justin Gregory |Schafer Boeder
Steve Edelman, MD: Egils we’ve talked about how to give teplizumab, and I think that was excellent because you don’t sit in the hospital for 14 days with 24 hours having an infusion. It’s 30 minutes. And I think even over time, they’re going to set up home health as you mentioned. Tell us the results of the TN10 study, which took a long time to recruit. Egils K. Bogdanovics, MD: It took a long time.
-
Aug 16, 2023 | 
contemporarypediatrics.com | Steve Edelman |Linda A. DiMeglio |Egils K. Bogdanovics |Justin Gregory |Schafer Boeder
Steve Edelman, MD: Well, I think now is the time to talk about teplizumab. Justin, I’ve assigned you to tell us a little bit about the drug, how it works, and about the results in the clinical trial, and how to give it, but we’re all going to help with that. Justin M. Gregory, MD, MSCI: Well, as you said, teplizumab is a monoclonal antibody that targets the CD3 receptor on T lymphocytes, and the CD3 receptor is a critical component of the T-cell receptor complex on the surface of T lymphocytes.
-
Aug 9, 2023 | 
hcplive.com | Steve Edelman |Linda A. DiMeglio |Egils K. Bogdanovics |Justin Gregory |Schafer Boeder
Steve Edelman, MD: I think it’s important to consider that the lab may not be correct. Some of the data’s coming out that you can have false positives. Linda A. DiMeglio, MD: Correct. Steve Edelman, MD: Which can do a mind game on parents and kids. I know Egils has some comments regarding interpreting some of these antibodies. Egils K. Bogdanovics, MD: Yes. Remember 2 antibodies. Stage I. It’s worth saying what antibodies we’re checking.
